newsfilter
← Latest News
GlobeNewswire·

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today